Return-Path: <contact@clinicaltrialmagnifier.com>
X-Spam-Checker-Version: SpamAssassin 3.1.3 (2006-06-01) on yquem.inria.fr
X-Spam-Level: **
X-Spam-Status: No, score=2.0 required=5.0 tests=DATE_IN_FUTURE_06_12,
	HTML_MESSAGE,HTML_MIME_NO_HTML_TAG,MIME_HTML_ONLY autolearn=disabled 
	version=3.1.3
X-Original-To: caml-list@yquem.inria.fr
Delivered-To: caml-list@yquem.inria.fr
Received: from mail1-relais-roc.national.inria.fr (mail1-relais-roc.national.inria.fr [192.134.164.82])
	by yquem.inria.fr (Postfix) with ESMTP id 4FD3CBBCA
	for <caml-list@yquem.inria.fr>; Mon, 17 Mar 2008 11:02:41 +0100 (CET)
X-IronPort-Anti-Spam-Filtered: true
X-IronPort-Anti-Spam-Result: At0sALLe3UfAXQIm/2dsb2JhbAA5ggYzAYxmgjKUYA
X-IronPort-AV: E=Sophos;i="4.25,512,1199660400"; 
   d="scan'208";a="9554422"
Received: from discorde.inria.fr ([192.93.2.38])
  by mail1-smtp-roc.national.inria.fr with ESMTP; 17 Mar 2008 11:02:41 +0100
Received: from mail3-relais-sop.national.inria.fr (mail3-relais-sop.national.inria.fr [192.134.164.104])
	by discorde.inria.fr (8.13.6/8.13.6) with ESMTP id m2HA2eRd002917
	(version=TLSv1/SSLv3 cipher=RC4-SHA bits=128 verify=OK)
	for <caml-list@inria.fr>; Mon, 17 Mar 2008 11:02:41 +0100
X-IronPort-Anti-Spam-Filtered: true
X-IronPort-Anti-Spam-Result: AtQfAPDe3UeTCEqEcmdsb2JhbAA5ggYzAYxmgSUBCQspT5Rf
X-IronPort-AV: E=Sophos;i="4.25,512,1199660400"; 
   d="scan'208";a="10349223"
Received: from unknown (HELO ClinicalTrialMagnifier.com) ([147.8.74.132])
  by mail3-smtp-sop.national.inria.fr with ESMTP; 17 Mar 2008 11:02:26 +0100
Received: from MIS-WW ([147.8.74.187]) by ClinicalTrialMagnifier.com with Microsoft SMTPSVC(6.0.3790.3959);
	 Mon, 17 Mar 2008 13:39:26 +0800
From: "Johan PE Karlberg" <contact@clinicaltrialmagnifier.com>
Subject: Clinical Trial Magnifier, Issue 2
To: caml-list@inria.fr
MIME-Version: 1.0
Date: Mon, 17 Mar 2008 21:39:26 +0000
Content-Type: text/html
Content-Transfer-Encoding: quoted-printable
Message-ID: <CTC-DEVELOPvZMFCZUJ00010f98@ClinicalTrialMagnifier.com>
X-OriginalArrivalTime: 17 Mar 2008 05:39:26.0929 (UTC) FILETIME=[437E7C10:01C887F1]
X-Miltered: at discorde with ID 47DE41C0.001 by Joe's j-chkmail (http://j-chkmail . ensmp . fr)!
X-Spam: no; 0.04; johan:01 johan:01 clinical:98 clinical:98 comprised:98 caml-list:01 data:02 hong:94 kong:91 feb:08 invited:09 university:10 analysis:11 monthly:87 newsletter:87 

<SPAN style=3D"mso-fareast-font-family: 'Times New Roman'"><SPAN style=
=3D"mso-fareast-font-family: 'Times New Roman'"><SPAN style=3D"mso-far=
east-font-family: 'Times New Roman'"><SPAN style=3D"mso-fareast-font-f=
amily: 'Times New Roman'">
<P><SPAN style=3D"mso-fareast-font-family: 'Times New Roman'"><SPAN st=
yle=3D"mso-fareast-font-family: 'Times New Roman'">Dear Colleague (cam=
l-list),</SPAN></SPAN></P>
<P><SPAN style=3D"mso-fareast-font-family: 'Times New Roman'">You are =
invited to subscribe to a new free electronic monthly newsletter, the =
Clinical Trial Magnifier at <A href=3D"http://www.clinicaltrialmagnifi=
er.com/" eudora=3D"autourl">www.clinicaltrialmagnifier.com</A>.</SPAN>=
</P>
<P><SPAN style=3D"mso-fareast-font-family: 'Times New Roman'"><SPAN st=
yle=3D"FONT-SIZE: 12pt; FONT-FAMILY: 'Times New Roman','serif'; mso-fa=
reast-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fa=
reast-language: EN-US; mso-bidi-language: AR-SA"><I>The second Issue (=
Feb 2008) - Sponsored Clinical Trial Globalization Trends<BR></I>The a=
nalysis data set comprised 5,167 industry-sponsored trials and 126,980=
 study sites. The United States, the "big five" European countries and=
 Canada continue to be leading trial locations worldwide, accounting f=
or 3 out of 4 sites. Emerging countries with large populations includi=
ng the four "BRIC" countries have become key sponsored clinical trial =
countries. Established study site locations with small populations are=
 losing out in this globalization process, e.g. the four Scandinavian =
countries. </SPAN></SPAN></P>
<P><SPAN style=3D"mso-fareast-font-family: 'Times New Roman'">Yours Si=
ncerely</SPAN></P>
<P><SPAN style=3D"mso-fareast-font-family: 'Times New Roman'">Johan PE=
 Karlberg, MD, PhD<BR>Clinical Trials Centre<BR>The University of Hong=
 Kong<BR>P.S. If you have any kind of queries or messages please conta=
ct me directly using: <BR><A href=3D"mailto:editorialboard@clinicaltri=
almagnifier.com">editorialboard@clinicaltrialmagnifier.com</A> </SPAN>=
</P></SPAN></SPAN></SPAN></SPAN>

